P53 Function Status Correlates With Overall Survival in Patients With Resected Pancreatic Cancer.

Area of Science:

• Oncology
• Genetics
• Cancer Research

Background:

• The P53 gene is frequently mutated in pancreatic ductal adenocarcinoma (PDAC).
• P53's normal function is vital for DNA repair, replication, and apoptosis.
• Mutations in P53 are common in PDAC, impacting tumor suppressor functions.

Purpose of the Study:

• To investigate the prognostic significance of different P53 mutation subtypes in resected PDAC.
• To determine if P53 mutation status impacts patient survival in pancreatic cancer.

Main Methods:

• Retrospective cohort study of 330 patients with resected PDAC (2016-2022).
• Next-generation sequencing (NGS) to analyze P53 tumor genotypes.
• Classification of P53 mutations into wild-type (WT), gain-of-function (GOF), and non-GOF subtypes.

Main Results:

• P53 mutations were identified in 74% of PDAC patients.
• Non-GOF P53 mutations were associated with significantly shorter overall survival (25.6 months) compared to WT (32.2 months) and GOF (36.2 months).
• Non-GOF mutations also correlated with reduced disease-free survival (14.6 months) versus WT (19.6 months) and GOF (18.3 months).

Conclusions:

• P53 mutation subtypes, categorized by functional status, possess differential prognostic value in PDAC.
• Findings suggest P53 mutation analysis can aid in predicting survival and recurrence in pancreatic cancer patients.
• Further research is needed to validate these prognostic implications of P53 mutations.